suMMARY Milrinone, a new bipyridine compound related to amrinone, is a potent non-adrenergic inotrope in experimental preparations and also shows vasodilator activity. In the present study the haemodynamic and metabolic effects of milrinone were evaluated in 12 patents with congestive heart failure. Milrinone 5 mg given orally produced a sharp reduction in left ventricular end diastolic pressure without significantly affecting stroke volume. The improvement in left ventricular function was due to a combination of vasodilatation and positive inotropism. Thus small reductions in blood pressure and systemic vascular resistance were associated with increments in the isovolumic indices of left ventricular function. The relation between left ventricular end systolic pressure and dimension was displaced leftwards and downwards. Only reductions in left ventricular cavity dimension were statistically significant, however. Though myocardial oxygen consumption did not change significantly, it tended to increase whereas lactate consumption tended to decrease.
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This trend towards oxygen imbalance suggests the need for caution in the use of milrinone in patients with severe coronary artery disease.
Milrinone is a recently introduced derivative of amrinone. Both compounds share a bipyridine ring structure and increase the contractility of isolated heart muscle.' The inotropic potency of milrinone, however, is 10-30 times greater than that of its parent compound.2 The mechanism of this inotropic effect remains unclear. Milrinone is a potent inhibitor of cyclic adenosine monophosphate adenylic acid (AMP) phosphodiesterase,l but peak increments in muscle tension precede maximal increase in intracellular cyclic AMP.2 Phosphodiesterase inhibition is unlikely, therefore, to account fully for the inotropic properties of the drug. In addition to its direct cardiac effects, milrinone also relaxes vascular smooth muscle in experimental preparations, though at considerably higher doses than are required to produce a positive inotropic response. dynamic responses to milrinone in patients with congestive heart failure.3-5 The contributions that positive inotropism and vasodilatation make towards the clinical efficacy of the drug are, however, unknown. This question is important because the balance of these separate cardiovascular influences largely determines the effects of treatment on myocardial oxygen demand-a consideration of particular relevance in patients with coronary artery disease.6
In the present study, therefore, we measured haemodynamic and metabolic responses to milrinone in patients with congestive heart failure. In particular, we evaluated the effects of this agent on left ventricular systolic function-as determined by contractile performance and loading conditions-and myocardial oxygen consumption.
Patients and methods

PATIENT SELECTION
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108 (12) 106 (12) 113 (14) 125 (21) 136 ( percentage. Myocardial uptake was calculated as the product of arteriocoronary sinus concentration difference in whole blood and coronary sinus flow.
STATISTICAL ANALYSIS
Two way analysis of variance was used to test the significance of the overall changes in individual haemodynamic and metabolic variables across time. Those variables which changed significantly (p<005) were then subjected to a modified t test-using the Bonferroni method-to identify the source of the differences.9
Results
No drug related side effects occurred during the study.
HAEMODYNAMIC RESPONSES Table 2 summarises the haemodynamic responses to milrinone and Fig. 1 shows the individual patient data. Table 3 gives the serum milrinone concentrations. The data in Tables 1 and 2 (5) 108 (5) 105 (6) 102 (5) 105 ( between end systolic pressure and dimension (Fig. 2) . The reduction in dimension was significant and was slightly more pronounced than the reduction in pressure (Table 4 ). In one patient reduction in the left ventricular end systolic cavity dimension occurrred during a progressive increase in pressure (Fig. 2a) . More commonly, however, small reductions in end systolic pressure were observed (Fig. 2b) .
METABOLIC RESPONSES In studies of this type analysis of the mechanisms responsible for changes in left ventricular function is difficult. The effects of milrinone on the isovolumic indices of left ventricular performance and the relation between end systolic pressure and dimension, however, strongly suggest a positive inotropic response to the drug. The isovolumic indices of ventricular performance provide a measure of contractile function but are also influenced by heart rate and loading conditions.10 1 1 In the present study the changes in loading that occurred in response to milrinone would have tended to reduce left ventricular max dP/dt.'I Because atrial pacing controlled for changes in heart rate, the increase in left ventricular max dP/dt during the study is best explained by an increase in contractility. Left ventricular max dP/dt/P is less susceptible to the influence of loading conditions,"I and the drug induced improvement in this measure of contractile function strengthens the conclusion that positive inotropism contributed towards the beneficial effects of milrinone.
The leftward displacement of the relation between left ventricular end systolic pressure and dimension that occurred in response to milrinone was due to a Acute responses to milrinone in heart failure significant reduction in cavity dimension. The reduction in end systolic pressure was not significant (unlike the change in peak systolic pressure measured in larger numbers of patients). Indeed in one case left ventricular pressure increased during simultaneous reductions in cavity dimension. Though we have previously emphasised the caution that is necessary in interpreting data of this type'2 (extrapolation from pressure-volume relations in the normal heart to pressure-dimension relations in the failing heart has not, as yet, been validated experimentally'3) the reduction in end systolic dimension without pronounced alteration in end systolic pressure suggests a positive inotropic response to the drug. 14 The response to milrinone should be contrasted with the response to felodipine-a potent vasodilator-which produces a pronounced downward displacement in the relation between the end systolic pressure and dimension in patients with heart failure.'2
The useful reduction in left ventricular filling pressures that occurred during this study is explained in part by the effects of milrinone on diastolic ventricular function. Preliminary work has shown that this drug improves indices of left ventricular diastolic relaxation and chamber distensibility in patients with heart failure."' Our finding of a significant increase in left ventricular min dP/dt supports this observation. Associated systemic venous pooling, however, is likely to have contributed to the reduction in ventricular filling pressures, and the small reductions in blood pressure and systemic vascular resistance point to associated arteriolar dilatation. Vasodilatation, therefore, appears to make an important contribution to the beneficial haemodynamic effects of milrinone as indicated by the data of Cody et al. 16 The metabolic consequence of antifailure treatment is an important consideration in the assessment of new agents. Milrinone produced a small increase in heart rate in addition to enhancing contractility. Increments in myocardial oxygen demand, however, were to some extent offset by associated reductions in wall tension caused by diminished left ventricular cavity dimensions and vasodilatation. ' 
